CRISPR-Cas9 has emerged as a highly effective and customizable tool for genome editing, holding promise for the treatment of KRAS mutations in lung cancer,60,71,72 however, developing an efficient and bio-safe material is a key barrier. This evidence concerns the gene KRAS and lung cancer.